Company: DNLI
Filing Date: 2025-02-27
Form Type: S-3ASR
Source: 0001628280-25-008647
Chunk: 2

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: S-3ASR
Chunk 2
---
 $400.0 million of our common stock that could be issued and sold from time to time under an equity distribution agreement with Goldman Sachs & Co. LLC, Leerink Partners LLC, and Cantor Fitzgerald & Co. as sales agents. As of immediately prior to the filing of this registration statement, $400.0 million of the registrant’s common stock remained available for sale under the Prior Equity Distribution Agreement Prospectus. Effective upon the filing of this registration statement, no further sales will be made under the Prior Equity Distribution Agreement Prospectus and instead such remaining shares may be offered and sold under this prospectus supplement.

The base prospectus immediately follows this explanatory note. The specific terms of any other securities to be offered pursuant to the base prospectus will be specified in one or more prospectus supplements to the base prospectus. The equity distribution agreement prospectus supplement immediately follows the base prospectus.

#### PROSPECTUS

#### DENALI THERAPEUTICS INC.

#### Common Stock

#### Preferred Stock

#### Debt Securities

#### Warrants

#### Purchase Contracts

#### Units
<div align='center'>________________________________________</div>

We may offer and sell the securities identified above from time to time in one or more offerings. This prospectus provides you with a general description of the securities.

Each time we offer and sell securities, we will provide a supplement to this prospectus that contains specific information about the offering and the amounts, prices and terms of the securities. The supplement may also add, update or change information contained in this prospectus with respect to that offering. You should carefully read this prospectus and the applicable prospectus supplement, together with any documents we incorporated by reference, before you invest in any of our securities.

We may offer and sell the securities described in this prospectus and any prospectus supplement to or through one or more underwriters, dealers and agents, or directly to purchasers, or through a combination of these methods. If any underwriters, dealers or agents are involved in the sale of any of the securities, their names and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement. See the sections of this prospectus entitled "About this Prospectus" and "Plan of Distribution" for more information. No securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of the offering of such securities.

<div align='center'>________________________________